| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |